Assessment of tumor vascularization: Immunohistochemical and non-invasive methods

International Journal of Biological Markers

Volumn 14, Issue 4, 1999, Pages 218-231

  Fanelli, M ^a   Locopo, N ^a   Gattuso, D ^a   Gasparini, G ^a  

^a BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

Author keywords

Determination of angiogenesis

Indexed keywords

CANCER ANTIBODY; TAMOXIFEN;

ANGIOGENESIS; CANCER CHEMOTHERAPY; CELL PROLIFERATION; CONFERENCE PAPER; DOPPLER ECHOCARDIOGRAPHY; ENDOTHELIUM CELL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTASIS; NEOVASCULARIZATION (PATHOLOGY); NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PREDICTION; SOLID TUMOR; TUMOR GROWTH; TUMOR VASCULARIZATION;

EID: 0033374557     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.1177/172460089901400405     Document Type: Conference Paper

References (110)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-6.
2. Folkman J. The role of angiogenesis in tumor growth. Sem Cancer Biol 1992; 3: 65-72.
3. Folkman J. Tumor angiogenesis. In: Holland J, Frei E, Bast RC, eds. Cancer medicine, IVth ed. Melbourne: Lea and Febiger 1993; 153-71.
4. Battegay E. Angiogenesis: Mechanistic insight, neovascular diseases, and therapeutic prospects. J Mol Med 1995; 73: 333-46.
5. Knighton-D, Ausprunk-D, Tapper D, Folkman J: Avascular and vascular phases of tumor growth in the chick embryo. Br J Cancer 1977; 35: 347-56.
6. Folkman J: What is the evidence that tumors are angiogenesis-dependent? J Natl Cancer Inst 1990; 82: 4-6.
7. Folkman J, Shing Y: Angiogenesis. J Biol Chem 1992; 267: 10931-4.
8. D'Amore PA. Capillary growth: a two-cell system. Cancer Biol 1992; 3: 49-56.
9. Schlingemann RO, Rietveld FYR, de Wall, RMW, Ferrone S, Ruiter DJ. Expression of the high molecular weight melanoma-associated antigen by pericytes during angiogenesis in tumors and in healing wounds. Am J Pathol 1990; 136: 1393-405.
10. Marks RM, Roche WR, Czerniecki M, Penny R, Nelson DS. Mast cell granules cause proliferation of human microvascular endothelial cells. Lab Invest 1986; 55: 289-94.
11. Leibovich SJ, Polverini PJ, Shepard HM, Wiseman DM, Shively V, Nuseir N. Macrophage induced angiogenesis is mediated by tumor necrosis factor-α. Nature 1987; 329: 630-2.
12. Hlatky L, Tsionou C, Hahnfeldt PH, Coleman CN. Mammary fibroblasts may influence breast tumor angiogenesis via hypoxia-induced vascular endothelial growth factor upregulation and protein expression. Cancer Res 1994; 54: 6083-6.
13. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994; 265: 1582-5.
14. Kieser A, Wiech HA, Brandner G, Marmé D, Kolch W. Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene 1994; 9: 963-9.
15. Mason IJ. The ins and outs of fibroblast growth factors. Cell 1994; 78: 547-52.
16. Tuszynski GP, Rothman V, Murphy A, et al. Thrombospondin promotes cell-substratum adhesion. Science 1987; 236: 1570-3.
17. D'Amore PA, Smith SR. Growth factor effects on cells of the vascular wall: a survey. Growth Factors 1993; 8: 61-75.
18. Ingber DE. Control of capillary growth and differentiation by extracellular matrix. Use of a tensegrity (tensional integrity) mechanism for signal processing. Chest 1991; 99: 34-40.
19. Stetler-Stevenson WG, Aznavoorian S, Liotta LA. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol 1993; 9: 541-73.
20. Parums DV, Cordell JL, Micklem K, Heryet AR, Gatte KC, Mason DY. JC70: a new monoclonal antibody that detects vascular endothelium associated antigen on routinely processed tissue sections. J Clin Pathol 1990; 43: 752-7.
21. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med 1991; 324: 1-8.
22. Toi M, Inada K, Suzuki M, Tominaga T. Tumor angiogenesis in breast cancer: its importance as a prognostic indicator and the association with vascular endothelial growth factor expression. Breast Cancer Res Treat 1995; 36: 193-204.
23. Gasparini G. Quantification of intratumoral vascularisation predicts metastasis in human invasive solid tumors (Review). Oncol Rep 1994; 1: 7-12.
24. Gasparini G, Pozza F, Harris AL. Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients. J Natl Cancer Inst 1993; 85: 1206-19.
25. Gasparini G, Harris AL. Clinical importance of the determination of tumor angiogenesis in breast carcinoma: Much more than a new prognostic tool. J Clin Oncol 1995; 13: 765-82.
26. Gasparini G, Bevilacqua P, Boboldi E, et al. Predictive and prognostic markers in a series of patients with head and neck squamous cell invasive carcinoma treated with concurrent chemoradiation-therapy. Clin Cancer Res 1995; 1: 1375-83.
27. Gasparini G, Barbareschi M, Boracchi P, et al. Tumor angiogenesis predicts clinical outcome of node-positive breast cancer patients treated with adjuvant hormone therapy or chemotherapy. Cancer J Sci Am 1995; 1: 131-41.
28. Gasparini G, Fox SB, Verderio P, et al. Determination of angiogenesis adds information to estrogen receptor status in predicting the efficacy of adjuvant tamoxifen in node-positive breast cancer patients. Clin Cancer Res 1996; 2: 1191-8.
29. Delorme S, Knopp MV. Non-invasive vascular imaging: assessing tumor vascularity. Eur Radiol 1998; 8: 517-27.
30. Libutti SK, Choyke P, Carrasquillo JA, Bacharach S, Neumann RD. Monitoring responses to angiogenic agents using non-invasive imaging tests. Cancer J Sci Am 1999; 5: 252-6.
31. Degani N, Gusis V, Weinstein D, Fields S, Strano S. Mapping pathophysiological features of breast tumors by MRI at high spatial resolution. Nature Med 1997; 3: 780-2.
32. 3-targeted magnetic resonance imaging. Nature Med 1998; 4: 623-6.
33. Vermeulen PB, Gasparini G, Fox SB, et al. Quantification of angiogenesis in solid human tumors: an international consensus on the methodology and criteria of eval-uation. Eur J Cancer 1996; 32: 2474-84.
34. Augustin HG, Kozian DH, Johnson RC. Differentiation of endothelial cells: analysis of the constitutive and activated endothelial cell phenotypes. BioEssays 1994; 16: 901-6.
35. Ruiter DJ, Schlingemann RO, Rietveld FJR, de Waal RMW. Monoclonal antibody-defined human endothelial antigens as vascular markers. J Invest Dermatol 1989; 93: 25-32.
36. Vermeulen B, Verhoeven D, Fierens H, et al. Microvessel quantification in primary colorectal carcinoma: an immuno-histochemical study. Br J Cancer 1995; 71: 340-3.
37. Van de Rijn M, Rouse RV. CD34: a review. Appl Immunohistochem 1994; 2: 71-80.
38. Traweek ST, Kandalaft PL, Mehta P, Battifora H. The human hematopoietic progenitor cell antigen (CD34) in vascular neoplasia. Am J Clin Pathol 1991; 96: 25-31.
39. Parums DV, Cordell JL, Micklem K, Heryet AR, Gatter KC, Mason DY. JC70: a new monoclonal antibody that detects vascular endothelium associated antigen on routinely processed tissue sections. J Clin Pathol 1990; 43: 752-7.
40. Horak E, Leek R, Klenk N, et al. Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as an indicator of node metastasis and survival in breast cancer. Lancet 1992; 340: 1120-4.
41. Wang JM, Kumar S, Pye D, Haboubi N, Al-Nakib L. Breast carcinoma: comparative study of tumor vasculature using two endothelial-cell markers. J Natl Cancer Inst 1994; 86: 386-8.
42. Wang JM, Kumar S, Pye D, van Agthoven AJ, Krupinski J, Hunter RD. A monoclonal antibody detects heterogeneity in vascular endothelium of tumors and normal tissues. Int J Cancer 1993; 54: 363-70.
43. Burrows FJ, Derbyshire EJ, Tazzari PL, et al. Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. Clin Cancer Res 1995; 1: 1623-34.
44. 3 for angiogenesis. Science 1994; 264: 569-71.
45. 3: A new prognostic indicator in breast cancer. Clin Cancer Res 1998; 4: 2625-34.
46. De Jong JS, Van Diest PJ, Baak JPA. Methods in laboratory investigation. Heterogeneity and reproducibility of microvessel counts in breast cancer. Lab Invest 1995; 73: 922-6.
47. Gasparini G. Clinical significance of the determination of angiogenesis in human breast cancer: Update of the biological background and overview of the Vicenza studies. Eur J Cancer 1996; 32A: 2485-93.
48. Weidner N. Tumor angiogenesis: review of current applications in tumor prognostication. Sem Diagn Pathol, 1993; 10: 302-13.
49. Fregene TA, Khanuja PS, Noto AC, et al. Tumor-associated angiogenesis in prostate cancer. Anticancer Res 1993, 13: 2377-81.
50. Fox SB, Leek RD, Weekes MP, Withehouse RM, Gatter KC, Harris AL. Quantitation and prognostic value of breast cancer angiogenesis: Comparison of microvessel density, Chalkley count and computer image analysis. J Pathol 1995; 177: 275-83.
51. Dickinson AJ, Fox SB, Persad RA, Hollyer J, Sibley GNA, Harris AL. Quantification of angiogenesis as an independent predictor of prognosis in invasive bladder carcinomas. Br J Urol 1994; 74: 762-6.
52. Wakui S, Furusato M, Itoh T, et al. Tumor angiogenesis in prognostic carcinoma with and without bone marrow metastases: a morphometric study. J Pathol 1992; 168: 257-62.
53. Visscher D, Smilanetz S, Drozdowicz S, Wykes S. Prog-nostic significance of image morphometric microvessel enumeration in breast carcinoma. Anal Quant Cytol 1993; 15: 88-92.
54. Axelsson K, Ljung B, Moore D, et al. Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma. J Natl Cancer Inst 1995; 87: 997-1008.
55. Barbareschi M, Weidner N, Gasparini G, et al. Microvessel density quantification in breast carcinomas. Assessment by light microscopy vs. a computer-aided image analysis system. Appl Immunohistochem 1995; 3: 75-84.
56. Charpin C, Devictor B, Bergeret D, et al. CD31 quantitative immunocytochemical assays in breast carcinomas. Am J Clin Pathol 1995; 103: 443-8.
57. Simpson JF, Ahn C, Battifora M, Esteban JM. Endothelial area as a prognostic indicator for invasive breast carcinoma. Cancer 1996; 77: 2077-85.
58. Brem S, Cotran R, Folkman J. Tumor angiogenesis: a quantitative method for histologic grading. J Natl Cancer Inst 1972; 48: 347-56.
59. Srivastava S, Laidler P, Daies RP, Horgan K, Hughes LE. The prognostic significance of tumor vascularity in intermediate-thickness (0.76-4.00 mm thick) skin melanoma. Am J Pathol 1988; 133: 419-23.
60. Weidner N, Folkman J. Tumoral vascularity as a prognostic factor in cancer. In: De Vita VT, Hellman S, Rosenberg SA, eds. Important advances in oncology. Philadelphia: Lippincott and Raven 1996; 167-90.
61. Weidner M. Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol 1995; 147: 9-19.
62. Gasparini G. Prognostic and predictive value of intra-tumoral microvessel density in human solid tumors. In: Bickmell R, Lewis CE, Ferrara M, eds. Tumor angiogen-esis. Oxford: Oxford University Press, 1997; 29-44.
63. Gasparini G, Harris AL. Prognostic significance of tumor vascularity. In: Teicher BA, ed. Antiangiogenic agents in cancer therapy, edited by BA Teicher, Humana Press Inc., Totowa, NJ-USA, 1999.
64. Hall NR, Fish DE, Hunt N, Goldin RD, Gullino PI, Monson JRT. Is the relationship between angiogenesis and metastasis in breast cancer real? Surg Oncol 1992; 1: 223-9.
65. Van Hoef MEHN, Knox WF, Dhesi SS, Howell A, Shor AM. Assessment of tumor vascularity as a prognostic factor in lymph node negative invasive breast cancer. Eur J Cancer 1993; 29A: 1141-5.
66. Fontanini G, Vignati S, Lucchi M, et al. Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: a prospective study. J Natl Cancer Inst 1997; 89: 881-6.
67. Weidner N, Folkman J, Pozza F, et al. Tumor angiogenesis: A new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992; 74: 1875-87.
68. Macaulay VM, Fox SB, Zhang H, et al. Breast cancer angiogenesis and tamoxifen resistance. End Rel Cancer 1995; 2: 97-103.
69. Hollingsworth HC, Kohn EC, Steinberg SM, Rothenberg ML, Merino MJ. Tumor angiogenesis in advanced stage ovarian carcinoma. Am J Pathol 1995; 147: 33-41.
70. Gasparini G, Bonoldi E, Viale G, et al. Prognostic and predictive value of tumor angiogenesis in ovarian carcinomas. Int J Cancer (Pred Oncol) 1996; 69: 205-11.
71. Delorme S, Knopp MV. Non invasive vascular imaging: assessing tumor vascularity. Eur Radiol 1998, 8: 517-27.
72. Less JR, Skalak TC, Sevick EM, Jain RK. Microvascular architecture in a mammary carcinoma: branching patterns and vessel dimensions. Cancer Res 1991; 51: 265-73.
73. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995; 146: 1029-39.
74. Burns PN, Halliwell M, Welis PNT, Webb AJ. Ultrason-ic Doppler studies of the breast. Ultrasound Med Biol 1982; 8: 127-43.
75. Cosgrove DO, Kedar RP, Bamber JC, et al. Breast diseases: Color Doppler US in differential diagnosis. Radiology 1993; 189: 99-104.
76. Huber S, Delorme S, Knopp MV, et al. Breast tumors: computer-assisted quantitative assessment with color Doppler US. Radiology 1994; 192: 797-801.
77. Kedar RP, Cosgrove DO, Bamber JC, Bell DS. Automat-ed quantification of color Doppler signals: a preliminary study in breast tumors. Radiology 1995; 197: 39-43.
78. Madjar H, Sauerbrei W, Prompeler HJ, Wolfarth R, Guf-ler H. Color Doppler and duplex flow analysis for classification of breast lesions. Gynecol Oncol 1997; 64: 392-403.
79. Raza S, Baum JK. Solid breast lesions: evaluation with power Doppler US. Radiology 1997; 203: 164-8.
80. Steinkamp HJ, Maurer J, Cornehl M, Knobber D, Hettwer H, Felix R. Recurrent cervical lymphadenopathy: differential diagnosis with color-duplex sonography. Eur Arch Otorhinolaryngol 1994; 251: 404-9.
81. Sterns EE, SenGupta S, Saunders F, Zee B. Vascularity demonstrated by doppler ultrasound and immunohistochemistry in invasive ductal carcinoma of the breast. Breast Cancer Res Treat 1996; 40: 197-203.
82. Hsiech CY, Wu CC, Chen TN, et al. Clinical significance of intratumoral blood flow in cervical carcinoma assessed by color doppler ultrasound. Cancer 1995; 75: 2518-22.
83. van Dijke CF, Brasdl RC, Roberts TP, et al. Mammary carcinoma model: correlation of macromolecular contrast-enhanced MRI image characterizations of tumor microvasculature and histologic capillary density. Radiology 1996; 198: 813-8.
84. Stomper PC, Winston JS, Herman S, et al. Angiogenesis and dynamic MRI imaging gadolinium enhancement of malignant and benign breast lesions. Breast Cancer Res Treat 1997; 45: 39-46.
85. Buadu LD, Murakami J, Murayama S, et al. Breast lesions: correlation of contrast medium enhancement patterns on MRI images with histopathologic findings and tumor angiogenesis. Radiology 1996; 200: 639-49.
86. Buckley DL, Drew PJ, Mussurakis S, et al. Microvessel density of invasive breast cancer assessed by dynamic Gd-DTPA enhanced MRI. J Magn Reson Imaging 1997; 7: 461-4.
87. Buadu LD, Murakami J, Murayama S, et al. Patterns of peripheral enhancement in breast masses: correlation of findings on contrast medium enhanced MRI with histologic features and tumor angiogenesis. J Comput Assist Tomogr 1997; 21: 421-30.
88. Degami M, Gusis V, Weimstein D, Fielas S, Strano S. Mapping pathophysiological features of breast tumors by MRI at high spatial resolution. Nature Med 1997; 3: 780-2.
89. Hawignorst M, Knapstein PG, Knopp MV, et al. Uterine cervical carcinoma: Comparison of standard and pharmacokinetic analysis of time-intensity curves for assessment of tumor angiogenesis and patient survival. Cancer Res 1998; 58: 3598-602.
90. Knopp MV, Brix G, Junkermann HJ, Sinn HP. MR mammography with pharmacokinetic mapping for monitoring of breast cancer treatment during neoadjuvant therapy. Magn Reson Imaging Clin North Am 1994; 2: 633-58.
91. Knopp MV, Junkermann HJ, Sinn P. Therapy monitoring of neoadjuvant chemotherapy in breast cancer: potential and pitfalls. Eur Radiol 7 (Suppl 1) 1997: S242 (abstract).
92. Pham CD, Roberts TP, van Bruggen M, et al. Magnetic resonance imaging detects suppression of tumor vascular permeability after administration of antibody to vascular endothelial growth factor. Cancer Invest 1998; 16: 225-30.
93. 3 targeted magnetic resonance imaging. Nature Med 1998; 4: 623-6.
94. 3: a new prognostic indicator in breast cancer. Clin Cancer Res 1998; 4: 2625-34.
95. 3. Proc ASCO 1998; 17: 215a.
96. Libutti SK, Choyke P, Carrasquillo JA, Bacharach S, Neumann RD. Monitoring responses to antiangiogenic agents using nominative imaging tests. Cancer J Sci Am 1999; 5: 252-6.
97. Schelbett HR. Blood flow and metabolism by PET. Cardiol Clin 1994; 12: 303-15.
98. Brudin LH, Ithodes CG, Valind SO, et al. Regional structure function correlations in chronic obstructive lung disease measured with positron emission tomography. Thorax 1992; 47: 914-21.
99. Cross SJ, Lee I IS, Metcalfe MJ, et al. Assessment of left ventricular regional wall motion with blood pool tomography: comparison of CO PET with 99Tcm Spect. Nucl Med Commun 1994; 15: 283-8.
100. Greven KM, Williams DW III, Keyes JW Jr, et al. Positron emission tomography of patients with head and neck carcinoma before and after high dose irradiation. Cancer 1994; 74: 1355-9.
101. Rege S, Maass A, Chaiken L, et al. Use of positron emission tomography with fluorodeoxyglucose in patients with extracranial head and neck cancers. Cancer 1994; 73: 3047-58.
102. Mukherji SK, Drane WE, Mancuso M, et al. Occult primary tumors of the head and neck: detection with 2-[F-18]fluoro-deoxy-D-glucose SPECT. Radiology 1996; 199: 761-6.
103. Keyes JW Jr, Watson NE Jr, Williams DW III, et al. FDG PET in head and neck cancer. Am J Roentgenol 1997; 169: 1663-9.
104. Hawkins RA, Hoh C, Dahioom M, et al. PET cancer evaluation with FDG. J Nucl Med 1991; 32: 1555-8.
105. Vansteenkiste J, Stroobants S, DeLeyn P, et al. Lymph node staging in non-small-cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients. J Clin Oncol 1998; 16: 2142-9.
106. Tomura N, Kato T, Kanno I, et al. Increased blood flow in human brain tumor after administration of angiotensin-II: demonstration by PET. Comput Med Imaging Graph 1993; 17: 443-9.
107. Mankoff DA, Dunnwald LK, Gralow JR, et al. Changes in blood flow and metabolism in locally advanced breast cancer in response to presurgical chemotherapy. J Nucl Med 1999; 40: 137.
108. Conti PS, Lilien DL, Hawley K, et al. PET and [ 18F]-FDG in oncology: a clinical update. Nucl Med Biol 1996; 23: 717-35.
109. DiChiro G. Positron emission tomography using [18F] fluorodeoxyglucose in brain tumors: a powerful diagnostic and prognostic tool. Invest Radiol 1986; 22: 360-71.
110. Valk PE, Abella-Columna E, Waseman MK, et al. Whole-body PET imaging with [18F] fluorodeoxyglucose in management of recurrent colorectal cancer. Arch Surg 1999; 134: 503-11.